Grifols reported a strong quarter with a decent recovery in the base business – the lynchpin Bioscience was the show-stopper, after a transient decline in Q1 21. While the improving plasma supply and sprawling collection base is soothing, the resurfacing pandemic and regulatory concerns in the US do warrant a caution. Also, while GIC’s investment does help to address leverage concerns, the resolution is only ‘partial’ and a full resolution is still awaited due to the (expected) continuation of o ....
02 Aug 2021
Strong Q2 helps regain ‘some’ lost mojo
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong Q2 helps regain ‘some’ lost mojo
- Published:
02 Aug 2021 -
Author:
Amandeep Goyal -
Pages:
3
Grifols reported a strong quarter with a decent recovery in the base business – the lynchpin Bioscience was the show-stopper, after a transient decline in Q1 21. While the improving plasma supply and sprawling collection base is soothing, the resurfacing pandemic and regulatory concerns in the US do warrant a caution. Also, while GIC’s investment does help to address leverage concerns, the resolution is only ‘partial’ and a full resolution is still awaited due to the (expected) continuation of o ....